Skip to main content
. 2017 May 23;55(6):1894–1901. doi: 10.1128/JCM.00346-17

TABLE 1.

Results of Zika NS1-based ELISA from 63 travelers with neutralization or RT-PCR positive Zika virus infection

Patient no. Country of origin Country of acquisition Gender/age (yr)a RT-PCR resultb Neutralization resultb 1st sampleb
 2nd sampleb
 3rd sampleb
 4th sampleb
Time from onset (days) IgM IgG Time from onset (days) IgM IgG Time from onset (days) IgM IgG Time from onset (days) IgM IgG
1 Czech Republic Martinique F/38 Neg Pos 3 Pos Neg 33 Equ Pos
2 Czech Republic Martinique F/43 Neg Pos 5 Equ Neg 59 Neg Pos
3 Czech Republic Dominican Republic F/49 Pos Pos 5 Neg Neg 10 Pos Pos 34 Pos Pos
4 Czech Republic Martinique M/58 Pos Pos 14 Pos Neg 27 Pos Pos 42 Pos Pos
5 Czech Republic Martinique M/44 Neg Pos 13 Pos Equ 38 Pos Pos
6 Czech Republic Martinique M/41 Neg Pos 19 Pos Pos 34 Pos Pos
7 Czech Republic Martinique F/42 NDc Pos 31 Pos Pos
8 Czech Republic/Slovakia Barbados, St. Vincent, St. Lucia M/33 Neg Pos 8 Pos Equ 31 Pos Pos
9 Czech Republic Dominican Republic F/64 Pos Pos 4 Pos Neg
10 Czech Republic Guadeloupe F/43 Pos Pos 3 Neg Neg 7 Pos Equ 15 Pos Pos 35 Pos Pos
11 Czech Republic/Slovakia Guadeloupe M/41 Pos Pos 3 Neg Neg 17 Pos Pos
12 Czech Republic Nicaragua M/31 Pos (semen) Pos 11 Pos Pos 15 Pos Pos 61 Neg Pos
13 Czech Republic/Israel Mexico M/26 Neg Pos 14 Pos Neg
14 Czech Republic Nicaragua F/31 Pos Pos 4 Neg Neg 6 Pos Neg 21 Equ Pos
15 Czech Republic Mexico F/23 Neg Pos 26 Pos Pos
16 Czech Republic/France Martinique M/40 Pos Equ 3 Neg Neg
17 Czech Republic Martinique M/7 ND Pos 33 Neg Pos
18 Czech Republic Nicaragua F/34 ND Pos 182 Neg Equ
19 Czech Republic Colombia M/32 ND Pos ∼360 Neg Equ
20 Czech Republic Colombia F/27 ND Pos ∼360 Neg Equ
21 Czech Republic French Polynesia M/65 ND Pos ∼1,000 Neg Pos
22 Belgium Venezuela M/45 Pos ND 4 Neg Neg 11d Pos Equ
23 Belgium Venezuela M/4 Pos ND 3d Neg Neg
24 Belgium Brazil F/28 Pos ND 11d Pos Pos 22 Pos Pos
25 Belgium Martinique M/66 Neg Pos 20 Pos Pos
26 Belgium Martinique F/66 Neg Pos 23 Pos Pos
27 Belgium Martinique M/46 Neg Pos 19 Pos Pos
28 Belgium Suriname F/20 Neg Pos ±80 Neg Pos
29 Chile Brazil F/25 Pos ND 1 Neg Neg
30 Chile Brazil M/35 Pos ND 3 Neg Neg
31 Chile Venezuela F/17 Pos ND 4 Pos Neg
32 Chile Colombia M/40 Pos ND 6 Pos Neg
33 Chile Dominican Republic M/39 Pos ND 2 ND ND 240 ND Neg
34 Chile Costa Rica M/25 Pos ND 2 Neg Neg
35 Italy Thailand M/32 Neg Pos 5 Pos ND 39 Equ ND 110 Neg ND
36 Italy Italye F/30 Neg Pos 2 Pos ND 36 Pos ND 90 Neg ND
37 Italy Brazil M/74 ND Pos 40 Pos ND
38 Italy Haiti M/34 ND Pos 16 Pos ND
39 Italy Venezuela F/42 Pos Pos 7 Pos Pos 14 Pos Pos 49 Equ Pos
40 Italy Martinique, Guadalupe F/34 Pos Equ 4 Equ ND
41 Italy Dominican Republic F/51 Pos Pos 7 Equ ND
42 Italy Venezuela F/32 Neg Pos 75 Neg ND
43 Italy Venezuela M/30 ND Pos 79 Neg ND
44 Italy Brazil F/37 ND Pos 62 Neg ND
45 Israel Colombia F/50 Pos Pos 5 Pos Pos 20 Neg Pos
46 Israel Colombia F/32 Pos Pos 10 Pos Pos 53 Neg Pos
47 Israel Vietnam M/61 Pos Neg 10 Pos Neg 58 Neg Neg
48 Israel Dominican Republic M/30 Pos Pos 26 Pos Pos 46 Neg Pos
49 Israel Guatemala, Mexico F/30 Pos Neg 26 Neg Neg 48 Neg Neg
50 Israel Colombia M/38 Neg Pos 34 Equ Pos
51 Israel Jamaica M/23 Pos Pos 11 Pos Equ 25 Pos Pos 49 Neg Pos
52 Israel USA (Miami) F/30 Pos Pos 8 Pos Neg
53 Israel Costa Rica M/27 Pos Pos 7 Pos Neg 18 Equ Equ 37 Neg Pos
54 Israel Mexico M/26 Pos Pos 27 Equ Pos 52 Neg Pos
55 Israel Mexico F/30 Pos Pos 12 Pos Equ 15 Pos Pos 29 Equ Pos 50 Neg Pos
56 Israel Mexico M/37 Pos Pos 5 Neg Neg 14 Pos Neg 28 Pos Pos 59 Neg Neg
57 Israel Costa Rica M/26 Pos Pos 6 Neg Neg 11 Pos Neg
58 Israel Costa Rica M/20 Neg Pos 29 Pos Pos
59 Israel Mexico/Cuba F/21 Pos ND 6 Neg Neg 16 Pos Pos
60 Germany Martinique M/56 Pos ND 3 Pos Neg 8 Pos Pos
61 Germany Martinique F/53 Pos ND 12 Equ Neg 16 ND Pos
62 Germany Guadeloupe M/33 Pos ND 11 Pos Neg
63 Germany Guadeloupe F/29 Pos ND 6 Pos Neg
a

F, female; M, male.

b

Pos, positive; Neg, negative; Equ, equivocal.

c

ND, not determined.

d

These samples were also part of another study (7).

e

This indicates an autochthonous transmission from patient 35 (15).